Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups

E Elizabeth J. Cathcart-Rake (Department of Medical Oncology, Mayo Clinic, Rochester, MN) V Viengneesee Thao (Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN) J Jennifer Le-Rademacher (Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN) D David A. Helfinstine (Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN) K Kathryn J. Ruddy C Celine Vachon C Caroline Davidge-Pitts (Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN) E Evelyn Carroll (Department of Radiology, Mayo Clinic, Rochester, MN) N NFN Scout (National LGBT Cancer Network, Providence, RI) J Jennifer L. Ridgeway (Division of Health Care Delivery Research, Mayo Clinic, Rochester, MN) C Chrisandra L. Shufelt (Division General Internal Medicine, Mayo Clinic, Jacksonville, FL) A Amye Tevaarwerk (Department of Medical Oncology, Mayo Clinic, Rochester, MN) A Aminah Jatoi (Department of Medical Oncology, Mayo Clinic, Rochester, MN)

Abstract

PURPOSE This national study was undertaken to determine screening mammography rates among transgender and gender diverse (TGD) individuals. METHODS TGD individuals and cisgender women who qualified to receive screening mammography based on American College of Radiology guidelines were identified in the longitudinal OptumLabs Data Warehouse. The primary end point was the percentage of patients who had high rates of screening (>75% recommended screenings). Multivariable analyses were conducted in a matched population of transgender men to cisgender women to identify and adjust for factors associated with high adherence. Individuals were matched at a 1:4 ratio (transgender men: cisgender women) on age, race/ethnicity, year of enrollment in their health care plan, and duration of follow-up. RESULTS This study focused on 10,478 TGD individuals (3,778 transgender men; 1,294 transgender women; 5,406 with gender dysphoria not meeting other TGD criteria, NMOT) and 6,218,369 cisgender women. For transgender men, transgender women, individuals with gender dysphoria NMOT, and cisgender women, high mammography rates were observed in 41.1% (95% CI, 39.5 to 42.6), 7.4% (95% CI, 6.0 to 8.8), 11.9% (95% CI, 11.0 to 12.7), and 38.3% (95% CI, 38.3 to 38.4), respectively ( P < .0001). When transgender men were compared with 15,112 matched cisgender women, an age-based differential association was observed between sex and high mammography rates (interaction P = .0003); compared with cisgender women, transgender men appeared more likely to manifest high rates of screening at age 40-49 years (odds ratios [ORs], 1.38 [95% CI, 1.28 to 1.50]; P < .0001) and 50-59 years (OR, 1.57 [95% CI, 1.35 to 1.81]; P < .0001) but not in the older age groups. CONCLUSION The relatively high rates of screening mammography in cisgender women and transgender men suggest clinicians are offering mammography to individuals who are at average or high breast cancer risk, as compared with cisgender women, and not to transgender women at low risk.

Article Details

Volume / Issue Vol. 44, Issue 11
Published April 10, 2026
Pages 981-991
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (13)

E

Elizabeth J. Cathcart-Rake

Department of Medical Oncology, Mayo Clinic, Rochester, MN

V

Viengneesee Thao

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN

J

Jennifer Le-Rademacher

Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN

D

David A. Helfinstine

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN

K

Kathryn J. Ruddy

C

Celine Vachon

C

Caroline Davidge-Pitts

Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN

E

Evelyn Carroll

Department of Radiology, Mayo Clinic, Rochester, MN

N

NFN Scout

National LGBT Cancer Network, Providence, RI

J

Jennifer L. Ridgeway

Division of Health Care Delivery Research, Mayo Clinic, Rochester, MN

C

Chrisandra L. Shufelt

Division General Internal Medicine, Mayo Clinic, Jacksonville, FL

A

Amye Tevaarwerk

Department of Medical Oncology, Mayo Clinic, Rochester, MN

A

Aminah Jatoi

Department of Medical Oncology, Mayo Clinic, Rochester, MN